JP7626491B2 - Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法 - Google Patents

Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法 Download PDF

Info

Publication number
JP7626491B2
JP7626491B2 JP2023505158A JP2023505158A JP7626491B2 JP 7626491 B2 JP7626491 B2 JP 7626491B2 JP 2023505158 A JP2023505158 A JP 2023505158A JP 2023505158 A JP2023505158 A JP 2023505158A JP 7626491 B2 JP7626491 B2 JP 7626491B2
Authority
JP
Japan
Prior art keywords
group
compound
salt
mmol
snc0dc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023505158A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022190626A5 (https=
JPWO2022190626A1 (https=
Inventor
均 笠井
恵太 谷田
良卓 小関
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of JPWO2022190626A1 publication Critical patent/JPWO2022190626A1/ja
Publication of JPWO2022190626A5 publication Critical patent/JPWO2022190626A5/ja
Application granted granted Critical
Publication of JP7626491B2 publication Critical patent/JP7626491B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
JP2023505158A 2021-03-12 2022-01-14 Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法 Active JP7626491B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021040799 2021-03-12
JP2021040799 2021-03-12
PCT/JP2022/001163 WO2022190626A1 (ja) 2021-03-12 2022-01-14 Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法

Publications (3)

Publication Number Publication Date
JPWO2022190626A1 JPWO2022190626A1 (https=) 2022-09-15
JPWO2022190626A5 JPWO2022190626A5 (https=) 2024-05-01
JP7626491B2 true JP7626491B2 (ja) 2025-02-04

Family

ID=83226544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505158A Active JP7626491B2 (ja) 2021-03-12 2022-01-14 Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法

Country Status (6)

Country Link
US (1) US20240300979A1 (https=)
EP (1) EP4306527A4 (https=)
JP (1) JP7626491B2 (https=)
CN (1) CN117015545A (https=)
AU (1) AU2022234045B2 (https=)
WO (1) WO2022190626A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115844891B (zh) * 2022-11-04 2025-02-11 沈阳药科大学 二硫键桥连的sn38二聚体前药及其自组装纳米粒、制备方法与应用
AU2023390747A1 (en) 2022-12-09 2025-06-26 Japan Science And Technology Agency Compound, nanoparticles, medicine and method for producing nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011155501A1 (ja) 2010-06-11 2011-12-15 独立行政法人科学技術振興機構 薬剤多量体微粒子及びその製造方法
JP2016534092A (ja) 2013-07-23 2016-11-04 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体
CN107669626A (zh) 2017-09-03 2018-02-09 河南师范大学 一种高载药量的还原敏感的药物传递系统的制备方法及其应用
JP2018520148A (ja) 2012-12-13 2018-07-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫抱合体
WO2019236954A1 (en) 2018-06-07 2019-12-12 Seattle Genetics, Inc. Camptothecin conjugates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021040799A (ja) 2019-09-09 2021-03-18 西川　基守 パチンコ遊技機

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011155501A1 (ja) 2010-06-11 2011-12-15 独立行政法人科学技術振興機構 薬剤多量体微粒子及びその製造方法
JP2018520148A (ja) 2012-12-13 2018-07-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫抱合体
JP2016534092A (ja) 2013-07-23 2016-11-04 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体
CN107669626A (zh) 2017-09-03 2018-02-09 河南师范大学 一种高载药量的还原敏感的药物传递系统的制备方法及其应用
WO2019236954A1 (en) 2018-06-07 2019-12-12 Seattle Genetics, Inc. Camptothecin conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUO, X. et al.，Dimeric Drug Polymeric Micelles with Acid-Active Tumor Targeting and FRET-Traceable Drug Release，Advanced Materials，2018年，Vol. 30，No. 3，pp. 1705436 (1 of 10)-1705436 (10 of 10)，Supporting Information
HE, D. et al.，Self-assembling nanowires of an amphiphilic camptothecin prodrug derived from homologous derivative，Chemical Communications，2016年，Vol. 52，No. 98，pp. 14145-14148，Supporting Information
WANG, H. et al.，Reduction-Responsive Dithiomaleimide-Based Nanomedicine with High Drug Loading and FRET-Indicated Dr，Chemical Communications，2015年，Vol. 51，No. 23，pp. 4807-4810，Supporting Information

Also Published As

Publication number Publication date
WO2022190626A1 (ja) 2022-09-15
EP4306527A4 (en) 2025-02-19
US20240300979A1 (en) 2024-09-12
JPWO2022190626A1 (https=) 2022-09-15
AU2022234045A1 (en) 2023-08-31
EP4306527A1 (en) 2024-01-17
AU2022234045B2 (en) 2025-05-29
CN117015545A (zh) 2023-11-07

Similar Documents

Publication Publication Date Title
TWI316942B (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US12152048B2 (en) Nitroxoline prodrug and use thereof
RU2466992C2 (ru) Моногидрат 4-[4-({[4-хлор -3(трифторметил)фенил]карбамоил}амино)-3-фторфенокси]-n-метилпиридин-2-карбоксамида
JP7626491B2 (ja) Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法
JP5844354B2 (ja) ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
WO2018171164A1 (zh) 一种喜树碱类前药及其制备和应用
JP7621289B2 (ja) ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用
JP2021147340A (ja) 化合物、そのナノ粒子及び癌疾患の治療剤
JP2008524218A (ja) ゲムシタビンのアミドプロドラック、組成物、及びそれらの使用
US9650390B2 (en) Water-soluble taxane derivatives and uses thereof
WO2011047530A1 (zh) 类胡萝卜素衍生物及其制备方法和应用
KR101996229B1 (ko) 지방산이 결합된 엔테카비어 유도체 화합물 및 이의 약학적 용도
JP2020528891A (ja) 変化したｔｃａ回路代謝に関連する状態を処置するための組成物および方法
JP5622856B2 (ja) キサントン誘導体およびその用途
US10906898B2 (en) Cocrystal
WO2005061492A1 (ja) 含窒素複素環化合物およびそれらを有効成分とする薬剤
TW202334176A (zh) 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物
EP4631949A1 (en) Compound, nanoparticles, medicine and method for producing nanoparticles
JP2021514353A (ja) ベンゾジアゼピン誘導体塩酸塩および結晶形、その製造方法および用途
KR20260028651A (ko) 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
TW202130619A (zh) 硝羥喹啉前藥及其用途
HK40047998A (en) Nitroxoline prodrug and use thereof
TW202222302A (zh) 麩醯胺酸類似物
CN102050856A (zh) 具有高活性的表阿霉素的衍生物及其制备和应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250116

R150 Certificate of patent or registration of utility model

Ref document number: 7626491

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150